JLE

Hématologie

MENU

Functional and clinical aspects of the anti-hemophilic bispecific antibody emicizumab Volume 26, issue 6, Décembre 2020

  • [1] Mannucci P.M., Tuddenham E.G. The hemophilias-from royal genes to gene therapy. N Engl J Med. 2001;344:1773-1779.
  • [2] White G.C., Rosendaal F., Aledort L.M. Definitions in hemophilia recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.
  • [3] Manco-Johnson M.J., Abshire T.C., Shapiro A.D. Prophylaxis episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535-544. versus
  • [4] Nilsson I.M., Berntorp E., Lofqvist T., Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25-32.
  • [5] Armstrong E.P., Malone D.C., Krishnan S., Wessler M.J. Costs and utilization of hemophilia A and B patients with and without inhibitors. J Med Econ. 2014;17:798-802.
  • [6] Fischer K., Steen Carlsson K., Petrini P. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013;122:1129-1136.
  • [7] van Dijk K., van der Bom J.G., Lenting P.J. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica. 2005;90:494-498.
  • [8] Gouw S.C., van der Bom J.G., Ljung R. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368:231-239.
  • [9] Peyvandi F., Mannucci P.M., Garagiola I. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054-2064.
  • [10] Eckhardt C.L., van Velzen A.S., Peters M. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122:1954-1962.
  • [11] van Velzen A.S., Eckhardt C.L., Hart D.P. Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thromb Haemost. 2015;114:46-55.
  • [12] Chowdary P., Lethagen S., Friedrich U. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13:743-754.
  • [13] Sehgal A., Barros S., Ivanciu L. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21:492-497.
  • [14] Shapiro A.D., Angchaisuksiri P., Astermark J. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134:1973-1982.
  • [15] Ferrante F., Inghma S., Kunze M., Michaels L.A. Anti-TFPI antibody BAY 1093884: early termination of phase II dose escalation study dur to thrombosis. Haemophilia. 2020;26:P099.
  • [16] Pasi K.J., Rangarajan S., Georgiev P. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377:819-828.
  • [17] Machin N., Ragni M.V. An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med. 2018;9:135-140.
  • [18] Kitazawa T., Igawa T., Sampei Z. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570-1574.
  • [19] Muto A., Yoshihashi K., Takeda M. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014;124:3165-3171.
  • [20] Sampei Z., Igawa T., Soeda T. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8:e57479.
  • [21] Kitazawa T., Esaki K., Tachibana T. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117:1348-1357.
  • [22] Lenting P.J., Denis C.V., Christophe O.D. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130:2463-2468.
  • [23] Lapan K.A., Fay P.J. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem. 1997;272:2082-2088.
  • [24] Lenting P.J., van Mourik J.A., Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92:3983-3996.
  • [25] Mertens K., Celie P.H., Kolkman J.A., Lenting P.J. Factor VIII-factor IX interactions: molecular sites involved in enzyme-cofactor complex assembly. Thromb Haemost. 1999;82:209-217.
  • [26] Duffy E.J., Parker E.T., Mutucumarana V.P., Johnson A.E., Lollar P. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem. 1992;267:17006-17011.
  • [27] Lenting P.J., Donath M.J., van Mourik J.A., Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem. 1994;269:7150-7155.
  • [28] Takeyama M., Wakabayashi H., Fay P.J. Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. Biochemistry. 2012;51:820-828.
  • [29] Oldenburg J., Mahlangu J.N., Kim B. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809-818.
  • [30] Agbani E.O., van den Bosch M.T., Brown E. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation. 2015;132:1414-1424.
  • [31] Nesheim M.E., Pittman D.D., Wang J.H., Slonosky D., Giles A.R., Kaufman R.J. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem. 1988;263:16467-16470.
  • [32] Gilbert G.E., Novakovic V.A., Shi J., Rasmussen J., Pipe S.W. Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine. Blood. 2015;126:1237-1244.
  • [33] Rosenberg J.S., McKenna P.W., Rosenberg R.D. Inhibition of human factor IXa by human antithrombin. J Biol Chem. 1975;250:8883-8888.
  • [34] Schmaier A.H., Dahl L.D., Rozemuller A.J. Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa. . J Clin Invest. 1993;92:2540-2545.
  • [35] Potgieter J.J., Damgaard M., Hillarp A. One-stage chromogenic assays in haemophilia A. Eur J Haematol. 2015;94:38-44. vs.Suppl 77
  • [36] Peyvandi F., Oldenburg J., Friedman K.D. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14:248-261.
  • [37] Rosen S., Andersson M., Blomback M. Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost. 1985;54:818-823.
  • [38] Lenting P.J. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv. 2020;4:2111-2118.
  • [39] Uchida N., Sambe T., Yoneyama K. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127:1633-1641.
  • [40] Adamkewicz J.I., Chen D.C., Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019;119:1084-1093.
  • [41] Nogami K., Soeda T., Matsumoto T., Kawabe Y., Kitazawa T., Shima M. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost. 2018;16:1383-1390.
  • [42] Shinohara S., Saito T., Noguchi-Sasaki M., Ishiwata T., Morris M. Evaluation of emicizumab calibrator and controls with a modified one-stage FVIII assay on an automated coagulation analyzer. Res Pract Thromb Haemost. 2019;3:PB1305.
  • [43] Wilmot H., Hogwood J., Williams S., Jennings I., Kitchen S., Walker I., Gray E. Laboratory measurement of emicizumab requires a product specific calibrator. Res Pract Thromb Haemost. 2019;3:PB1190.
  • [44] Lance M.D. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J. 2015;13:1.
  • [45] Calzavarini S., Brodard J., Quarroz C., e al. Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: normal values and variability. Res Pract Thromb Haemost. 2019;3:758-768.
  • [46] Chelle P., Montmartin A., Piot M. Prediction of individual factor VIII or IX level for the correction of thrombin generation in haemophilic patients. Haemophilia. 2018;24:995-1001.
  • [47] Dargaud Y., Beguin S., Lienhart A. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005;93:475-480.
  • [48] Olsson A., Hellgren M., Berntorp E., Holmstrom M., Baghaei F. Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation. Haemophilia. 2015;21:e111-e113.
  • [49] Santagostino E., Mancuso M.E., Tripodi A. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost. 2010;8:737-743.
  • [50] Young G., Sorensen B., Dargaud Y., Negrier C., Brummel-Ziedins K., Key N.S. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013;121:1944-1950.
  • [51] Dargaud Y., Lienhart A., Janbain M., Le Quellec S., Enjolras N., Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018;103:e181-e183.
  • [52] Kizilocak H., Yukhtman C.L., Marquez-Casas E., Lee J., Donkin J., Young G. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019;10:2040620719860025.
  • [53] Muto A., Yoshihashi K., Takeda M. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12:206-213.
  • [54] Ferriere S., Peyron I., Christophe O.D. A hemophilia A mouse model for the assessment of emicizumab function. Blood. 2020;136:740-748. in vivo6
  • [55] Shima M., Hanabusa H., Taki M. Factor VIII-Mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044-2053.
  • [56] Young G., Liesner R., Chang T. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127-2138.
  • [57] Mahlangu J., Oldenburg J., Paz-Priel I. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811-822.
  • [58] Pipe S.W., Shima M., Lehle M. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295-e305.
  • [59] Makris M., Iorio A., Lenting P.J. Emicizumab and thrombosis: the story so far. J Thromb Haemost. 2019;17:1269-1272.
  • [60] Levy G.G., Asikanius E., Kuebler P., Benchikh El Fegoun S., Esbjerg S., Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019;17:1470-1477.
  • [61] Holstein K., Liu X., Smith A. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood. 2020;136:279-287.
  • [62] Weyand A.C., Flood V.H., Shavit J.A., Pipe S.W. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Adv. 2019;3:2748-2750.
  • [63] Minami H., Nogami K., Yada K. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma . J Thromb Haemost. 2019;17:126-137. in vitro
  • [64] Yada K., Nogami K., Novel Insights. New developments regarding coagulation revealed by studies of the anti-factor IXa (activated factor IX)/factor X bispecific antibody, emicizumab. Arterioscler Thromb Vasc Biol. 2020;40:1148-1154.